Quick Search 
Methods and Findings
Register or sign in

  
 
  
Methods Find Exp Clin Pharmacol 2010, 32(2): 133
ISSN 0379-0355
Copyright 2010 Clarivate Analytics
CCC: 0379-0355
 



Gateways to Clinical Trials

A. Tomillero and M.A. Moral

Thomson Reuters, Provença 388, 08025 Barcelona, Spain



Summary

Alemtuzumab, Atomoxetine hydrochloride; BioMatrix Flex drug-eluting stent, Botulinum toxin type B, Brivaracetam; Cannabidiol, Carisbamate, Cetuximab, Ciclesonide; Daptomycin, Darunavir, Duloxetine hydrochloride; Ecallantide, Enfuvirtide, Etravirine, Everolimus-eluting coronary stent, Ezetimibe; Fluticasone furoate, FX-125L; Ghrelin (human); Idraparinux sodium; Lersivirine, Levocetirizine dihydrochloride, Levodopa/carbidopa/entacapone, Liposomal doxorubicin, LNCaP/IL-2/IFN-gamma; Morphine hydrochloride; Natalizumab; Olmesartan medoxomil; Paclitaxel-eluting stent, Perampanel, Pertuzumab, Pregabalin; Rasagiline mesilate, Rimonabant, Riociguat, Roflumilast, Rosuvastatin calcium, Rufinamide; Sirolimus-eluting stent; Tadalafil, Telavancin hydrochloride, Telmisartan/amlodipine besilate, Tenofovir disoproxil fumarate/emtricitabine, Tolvaptan; Valganciclovir hydrochloride, Vinflunine; Zotarolimus-eluting stent. Copyright © 2010 Prous Science, S.A.U. or its licensors. All rights reserved.



Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy